Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Creative Medical Technology Holdings (CELZ) Research & Development (2016 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed Research & Development for 8 consecutive years, with $465154.0 as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 20.05% to $465154.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.2 million, a 4.25% decrease, with the full-year FY2024 number at $2.4 million, up 21.83% from a year prior.
  • Research & Development was $465154.0 for Q3 2025 at Creative Medical Technology Holdings, down from $501261.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.4 million in Q4 2022 to a low of $10000.0 in Q1 2022.
  • A 5-year average of $732892.3 and a median of $465154.0 in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 10636.44% in 2022, then tumbled 93.49% in 2023.
  • Creative Medical Technology Holdings' Research & Development stood at $50000.0 in 2021, then soared by 10636.44% to $5.4 million in 2022, then crashed by 93.49% to $349408.0 in 2023, then skyrocketed by 35.04% to $471840.0 in 2024, then decreased by 1.42% to $465154.0 in 2025.
  • Per Business Quant, the three most recent readings for CELZ's Research & Development are $465154.0 (Q3 2025), $501261.0 (Q2 2025), and $743304.0 (Q1 2025).